Sorrento reports positive data from oral Covid-19 treatment trial

Sorrento Therapeutics has reported positive data from a Phase Ib clinical trial of ovydso (STI-1558), an oral main viral protease (Mpro) inhibitor for Covid-19.

Conducted in China, the placebo-controlled, randomised, double-blind study was designed for evaluating the pharmacokinetics (PK), efficacy, tolerability, and safety of single and multiple STI-1558 oral doses in healthy volunteers, as well as Covid-19 patients.